Skip to main content

Reneo Pharmaceuticals, Inc. (RPHM)

NASDAQ: RPHM · IEX Real-Time Price · USD
6.69 -0.32 (-4.56%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap159.86M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out21.36M
EPS (ttm)-4.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume20,414
Open6.94
Previous Close7.01
Day's Range6.55 - 6.94
52-Week Range6.10 - 17.18
Betan/a
AnalystsStrong Buy
Price Target31.33 (+368.3%)
Est. Earnings DateNov 10, 2021

About RPHM

Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, C...

IndustryBiotechnology
IPO DateApr 9, 2021
Employees17
Stock ExchangeNASDAQ
Ticker SymbolRPHM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for RPHM stock is "Strong Buy." The 12-month stock price forecast is 31.33, which is an increase of 368.31% from the latest price.

Price Target
$31.33
(368.31% upside)
Analyst Consensus: Strong Buy

News

Reneo Pharmaceuticals Appoints Ashley Hall as Chief Development Officer

IRVINE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for pa...

1 week ago - GlobeNewsWire

Reneo Pharmaceuticals Hosting Key Opinion Leader Webinar on McArdle Disease and other Genetic Mitochondrial Myopathies

IRVINE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for p...

3 weeks ago - GlobeNewsWire

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

IRVINE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for p...

1 month ago - GlobeNewsWire

Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results

First patient dosed in STRIDE study of REN001 in primary mitochondrial myopathies First patient dosed in STRIDE study of REN001 in primary mitochondrial myopathies

2 months ago - GlobeNewsWire

Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction

SAN DIEGO, July 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patient...

3 months ago - GlobeNewsWire

Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results

SAN DIEGO, May 20, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients...

5 months ago - GlobeNewsWire

Reneo Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients...

5 months ago - GlobeNewsWire

Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM Stock IPO Begin Trading Today

Biotech stocks are making headlines on Friday as two companies join the public market via initial public offerings (IPOs) today. The post Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM...

Other symbols:VECT
6 months ago - InvestorPlace

Reneo Pharmaceuticals Announces Pricing of Initial Public Offering

SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, g...

6 months ago - GlobeNewsWire

Rare disease biotech Reneo Pharmaceuticals files for a $100 million IPO

Reneo Pharmaceuticals, a Phase 2 biotech developing therapies for rare genetic mitochondrial diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

7 months ago - NASDAQ

Reneo Pharmaceuticals IPO Registration Document (S-1)

Reneo Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

7 months ago - SEC